Curcumin for maintenance of remission in ulcerative colitis (original) (raw)
2012, The Cochrane database of systematic reviews
AI-generated Abstract
The review examines the efficacy of curcumin in maintaining remission in ulcerative colitis patients. Based on a single trial involving 89 patients, curcumin showed a lower relapse rate at six months compared to a placebo (4% vs 18%), though statistical significance was marginal (P=0.06). Clinical and endoscopic activity indices at six months also favored curcumin, with significant improvement over placebo (CAI MD -1.20; EI MD -0.80). At 12 months, relapse rates were not statistically significant. Adverse events were reported but not attributed to treatment groups.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.